Arvinas Holding Company (ARVN) has provided an update.
Arvinas, Inc. has struck a significant deal with Novartis Pharma AG, granting Novartis an exclusive global license to develop, manufacture, and commercialize Arvinas’s prostate cancer treatment, ARV-766. In addition to an initial $150 million payment to Arvinas, the agreement includes up to $1.01 billion in potential milestone payments, and tiered sales royalties. The transaction is contingent on regulatory approvals, and full details will be disclosed in future SEC filings. This partnership represents a promising development in prostate cancer therapy and a major financial milestone for Arvinas.
Find detailed analytics on ARVN stock on TipRanks’ Stock Analysis page.
